Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Eli Lilly (NYSE: LLY) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding ...

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

While the stock market has been on a strong winning streak recently, you should only be putting cash into stocks that you ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

Get the latest business headlines including trade deals, AI in airlines, and the surprising comeback of cottage cheese. Stay ...